You are here

Article info

Article menu
XML
Oncolytic and local immunotherapy
Original research
Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist

Authors

  • Shakoora A Sabree Interdisciplinary Graduate Program in Immunology, The University of Iowa, Iowa City, IA, USAMedical Scientist Training Program, The University of Iowa Carver College of Medicine, Iowa City, IA, USAHolden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • Andrew P Voigt Medical Scientist Training Program, The University of Iowa Carver College of Medicine, Iowa City, IA, USADepartment of Ophthalmology and Visual Sciences, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • Sue E Blackwell Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • Ajaykumar Vishwakarma Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USADivision of Pharmaceutics and Translational Therapeutics, The University of Iowa College of Pharmacy, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • Michael S Chimenti Iowa Institute of Human Genetics, University of Iowa Carver College of Medicine, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • Aliasger K Salem Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USADivision of Pharmaceutics and Translational Therapeutics, The University of Iowa College of Pharmacy, Iowa City, IA, USA PubMed articlesGoogle scholar articles
  • George J Weiner Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, USADivision of Pharmaceutics and Translational Therapeutics, The University of Iowa College of Pharmacy, Iowa City, IA, USADepartment of Internal Medicine, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA PubMed articlesGoogle scholar articles

Citation

Sabree SA, Voigt AP, Blackwell SE, et al
Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
Journal for ImmunoTherapy of Cancer 2021;9:e002484. doi: 10.1136/jitc-2021-002484
Online issue publication 
February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.